Biological agents for the treatment of uveitis

Bibliography

• Havener WA. Ocular Pharmacology. St. Louis: C.V. Mosby; 1983. p. 475-91
   Google Scholar
• Rajaraman RT, Kimura Y, Li S, Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006;113:308-14
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9
   PubMed Web of Science ®Google Scholar
• Hertz R. Folic Acid Antagonist. Effects on the cell and the patient. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 1963;59:931-56
   PubMed Web of Science ®Google Scholar
• Foster CS, Vitale AT. Diagnosis and treatment of uveitis. Sauders; Philadelphia: 2002. p. 177-214
   Google Scholar
• Borel JF. The History of cyclosporine A and its significance. In: White DJG, editor. Cyclosporine A. Elsevier Biomedical Press; New York: 1982. p. 5-17
   Google Scholar
• Whitcup SM, Hikita N, Shirao M, Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis. Exp Eye Res 1995;60:597-601
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Lamprecht P, Nolle B, Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005;64:1087-8
   PubMed Web of Science ®Google Scholar
• Baltatzis S, Tufail F, Yu EN, Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003;110:1061-5
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D, Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63(3):395-400
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88
   PubMed Web of Science ®Google Scholar
• Elsching A. Studien zur sympathischen ophthalmic. Die antigene wirkung des augenpigmentes. Graefes Arch Ophthalmol 1910;75:459
   Google Scholar
• Deeg CA, Reese S, Gerhards H, Kaspers B. The uveitogenic potential of retinal S-antigen in horses. Invest Ophthalmol Vis Sci 2004;45(7):2286-92
   PubMed Web of Science ®Google Scholar
• Adamus G, Amundson D. Epitope recognition of recoverin in cancer associated retinopathy: evidence for calcium-dependent conformational epitopes. J Neurosci Res 1996;45(6):863-72
   PubMed Web of Science ®Google Scholar
• Grajewski RS, Silver PB, Agarwal RK, Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J Exp Med 2006;203(4):851-6
   PubMed Web of Science ®Google Scholar
• Broekhuyse RM, Kuhlmann ED. Experimental autoimmune anterior uveitis. The preparation of uveitogenic ocular melanin. Invest Ophthalmol Vis Sci 1993;34(3):698-700
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002;69(1):12-18
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FH, Armbrust W, Factors associated with treatment. Response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306(21):2340-7
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Zhan S, Daclizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2010(6):CD008127
   Google Scholar
• Sheridan JP, Zhang Y, Riester K, Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler 2011;17(12):1441-8
   PubMed Web of Science ®Google Scholar
• Calabrese LH. Anakinra treatment of patients with rheumatoid arthritis. Ann Pharmacother 2002;36(7-8):1204-9
   PubMed Web of Science ®Google Scholar
• Hussar DA. New drugs of 2003. J Am Pharm Assoc 2004;44(2):168-206
   Google Scholar
• Elices MJ. Natalizumab. Elan/Biogen. Curr Opin Investig Drugs 2003;4(11):1354-62
   PubMedGoogle Scholar
• Hale G, Bright S, Chumbley G, Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983;62:873-82
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71
   PubMed Web of Science ®Google Scholar
• Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278(4):335-6
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144:55-61
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-9
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Mohle A, Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum 2010;62:2796-805
   PubMed Web of Science ®Google Scholar
• Kotter I, Zierhut M, Eckstein AK, Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-31
   PubMed Web of Science ®Google Scholar
• Wechsler B, Bodaghi B, Huong DL, Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 2000;8:293-301
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol 2011;129(3):288-94
   PubMed Web of Science ®Google Scholar
• El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye 2005;19:1017-18
   PubMed Web of Science ®Google Scholar
• Sobaci G, Bayraktar Z, Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005;13:59-66
   PubMed Web of Science ®Google Scholar
• Becker MD, Heiligenhaus A, Hudde T, Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005;89:1254-7
   PubMed Web of Science ®Google Scholar
• Horie Y, Kitaichi N, Takemoto Y, Polymorphism of IFN-gamma gene and Vogt-Koyanagi-Harada disease. Mol Vis 2007;13:2334-8
   PubMed Web of Science ®Google Scholar
• Chebil A, Kort F, Bouraoui R, Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection. J Fr Ophtalmol 2010;33(3):185-8
   PubMed Web of Science ®Google Scholar
• Lim JH, Lee YN, Kim YS, Vogt-Koyanagi-Harada disease occurring during pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C. Korean J Hepatol 2011
   Google Scholar
• Deuter CM, Koetter I, Guenaydin I, Interferon alpha-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006;26:786-91
   PubMed Web of Science ®Google Scholar
• Touitou V, Sene D, Fardeau C, Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword? Int Ophthalmol 2007;27(2-3):211-15
   PubMedGoogle Scholar
• Schaefer M, Engelbrecht MA, Gut O, Interferon alpha (IFN-alpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:731-46
   PubMed Web of Science ®Google Scholar
• Vo AA, Cam V, Toyoda M, Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol 2006;1:844-52
   PubMed Web of Science ®Google Scholar
• Jayne DR, Davies MJ, Fox CJ, Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991;337:1137-9
   PubMed Web of Science ®Google Scholar
• Blum M, Andrassy K, Adler D, Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement. Graefes Arch Clin Exp Ophthalmol 1997;235:599-602
   PubMed Web of Science ®Google Scholar
• LeHoang P, Cassoux N, George F, Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 2000;8:49-57
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, George Retinochoroidopathy RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 1999;127:545-9
   PubMed Web of Science ®Google Scholar
• Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol 2001;85:1287-8
   PubMed Web of Science ®Google Scholar
• Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002;102:59-67
   PubMed Web of Science ®Google Scholar
• Gonzalez-Delgado M, Gonzalez C, Blazquez JI, Intravenous immunoglobulin therapy in Vogt-Koyanagi-Harada syndrome. Neurologia 2004;19:401-3
   PubMed Web of Science ®Google Scholar
• Aharon A, Zandman-Goddard G, Schoenfeld Y. Autoimmune multiorgan involvement in elderly men is it SLE? Clin Rheumatol 1994;13:631-4
   PubMed Web of Science ®Google Scholar
• Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 2006;34:365-74
   PubMed Web of Science ®Google Scholar
• St Clair EW, Wagner CL, Fasanmade AA, The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9
   PubMed Web of Science ®Google Scholar
• Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, Tumor necrosis factor-alpha levels in aqueous humor and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 2004;20:155-7
   PubMed Web of Science ®Google Scholar
• Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010;35:751-6
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleiscmann RM, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW, Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, A trial of etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, Van Der Heijde D, Braun J, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2262-72
   Google Scholar
• Koizumi K, Poulaki V, Doehmen S, Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 2003;44:2184-91
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105
   PubMed Web of Science ®Google Scholar
• Arida A, Fragiadaki K, Giavri E, Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41:61-70
   PubMed Web of Science ®Google Scholar
• Smith JA, Thompson DJ, Whitcup SM, A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23
   PubMed Web of Science ®Google Scholar
• Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128:1062-7
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Horneff G, Greiner K, Inhibitors of tumor necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin Monatsbl Augenheilkd 2007;224:526-31
   PubMed Web of Science ®Google Scholar
• Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007;27:399-413
   PubMed Web of Science ®Google Scholar
• Tynjala P, Lindahl P, Honkanen V, Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, Efficacy of etanercept in preventing relapses of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-40
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK, Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8
   PubMed Web of Science ®Google Scholar
• Foster CS, Vitale AT. Diagnosis and Treatment of Uveitis. Sauders; Philadelphia: 2002. p. 177-214
   Google Scholar
• Smolen JS, Van Der Heijde DM, St Clair EW, Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K, Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-20
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dijkmans B, Geusens P, Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91
   PubMed Web of Science ®Google Scholar
• Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci 2007;48:3246-52
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12
   PubMed Web of Science ®Google Scholar
• Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol 2000;95:2395-6
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease. Int Ophthalmol 2005;26:83-92
   PubMedGoogle Scholar
• Accorinti M, Pirraglia MP, Paroli MP, Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007;51:191-6
   PubMed Web of Science ®Google Scholar
• Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 2005;19:841-5
   PubMed Web of Science ®Google Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, Van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthlmol 2005;89:533-6
   PubMed Web of Science ®Google Scholar
• Merino G, Varas G, Diaz G, Effectiveness of infliximab in patients with Behcet syndrome and severe uveoretinitis. Report of five cases. Rev Med Chil 2006;134:875-82
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Benucci M, Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology 2007;46:1161-4
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakamura S, Hori S, Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet's disease. Ann Intern Med 2004;140:404-6
   PubMed Web of Science ®Google Scholar
• Tongon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann NY Acad Sci 2007;1110:474-84
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Kaneko S, Induction of regulatory T cells by infliximab in Behcet's disease. Invest Ophthalmol Vis Sci 2011;52:476-84
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005;52:2478-84
   PubMed Web of Science ®Google Scholar
• Murphy CC, Ayliffe WH, Booth A, Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004;111:352-6
   PubMed Web of Science ®Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Theodossiadis PG, Katsiari CG, Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001;358:295-6
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Nielsen S, Kummerle-Deschner J, Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34:1146-50
   PubMed Web of Science ®Google Scholar
• Gallagher M, Quinones K, Cervantes-Castaneda RA, Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91:1341-4
   PubMed Web of Science ®Google Scholar
• Saurenmann RK, Levin AV, Rose JB, Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9
   PubMed Web of Science ®Google Scholar
• Adan A, Sanmarti R, Bures A, Casaroli-Marano RP. Successful treatment with infliximab in a patient with Diffuse Subretinal Fibrosis syndrome. Am J Ophthalmol 2007;143:533-4
   PubMed Web of Science ®Google Scholar
• Duzgun N, Ayaslioglu E, Tutkak H, Aydintug OT. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet's disease. Rheumatol Int 2005;25:1-5
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71
   PubMed Web of Science ®Google Scholar
• Joseph A, Raj D, Dua HS, Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-53
   PubMed Web of Science ®Google Scholar
• Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113:860-4
   PubMed Web of Science ®Google Scholar
• Simonini G, Zannin ME, Caputo R, Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford) 2008;47:1510-14
   PubMed Web of Science ®Google Scholar
• Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010;30:1530-5
   PubMed Web of Science ®Google Scholar
• Gupta SR, Phan IT, Suhler EB. Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch Ophthalmol 2011;129:250-2
   PubMed Web of Science ®Google Scholar
• Ito T, Sonoda KH, Hijioka K, Acquired resistance to infliximab against uveitis due to Behcet's disease after one year of administration. Jpn J Ophthalmol 2010;54:502-4
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M, Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH, Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Biester S, Deuter C, Michels H, Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91(3):319-24
   PubMed Web of Science ®Google Scholar
• Calvo J, Campos C, Rueda Cid A, Efficacy of adalimumab in Behcet's disease. Description of 6 cases. Reumatol Clin 2011;7:258-61
   Google Scholar
• Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye 2007;21:824-5
   PubMed Web of Science ®Google Scholar
• Diaz Llopi M, Amselem L, Romero FJ, Adalimumab therapy for Vogt-Koyanagi-Harada syndrome. Arch Soc Esp Oftalmol 2007;82:131-2
   PubMedGoogle Scholar
• Rudwaleit M, Rødevand E, Holck P, Adalimumab effectively reduces the rate of anterior uveitis flares in patients with acute ankylosing spondylitis: result of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
   PubMed Web of Science ®Google Scholar
• Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm 2010;18(3):226-32
   PubMed Web of Science ®Google Scholar
• Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-5
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011;63:612-18
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005;4:637-41
   PubMedGoogle Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M, Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204
   PubMed Web of Science ®Google Scholar
• Cohen SB, Woolley JM, Chan W, Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 2003;30:225-31
   PubMed Web of Science ®Google Scholar
• Cohen S, Hurd E, Cush J, Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24
   PubMed Web of Science ®Google Scholar
• Teoh SC, Sharma S, Hogan A, Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 2007;91:263-4
   PubMed Web of Science ®Google Scholar
• Lim WK, Fujimoto C, Ursea R, Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol 2005;123:957-63
   PubMed Web of Science ®Google Scholar
• Terrada C, Neven B, Boddaert N, Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. J Ophthalmic Inflamm Infect 2011;1:133-6
   PubMedGoogle Scholar
• El-Shabrawi YG, Christen WG, Foster SC. Correlation of metalloproteinase-2 and -9 with proinflammatory cytokines interleukin-1b, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis. Curr Eye Res 2000;20:211-14
   PubMed Web of Science ®Google Scholar
• Vincenti F, Kirkman R, Light S, Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338:161-5
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Fortin E, Schiffman R, Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999;96:7462-6
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Peterson JS, Foster CS, Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112:764-70
   PubMed Web of Science ®Google Scholar
• Hernandez Garfella ML, Diaz Llopis M, Salom Alonso D, Cervera Taulet E. Recurrent uveitis and therapy with monoclonal antibody (daclizumab). Arch Soc Esp Oftalmol 2004;79:593-8
   PubMedGoogle Scholar
• Nussenblatt RB, Thompson DJ, Li Z, Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003;21:283-93
   PubMed Web of Science ®Google Scholar
• Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003;11:786-9
   Google Scholar
• Sobrin L, Huang JJ, Christen W, Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 2008;126:186-91
   PubMed Web of Science ®Google Scholar
• Bhat P, Castaneda-Cervantes RA, Doctor PP, Foster CS. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 2009;247:687-92
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM194907.pdf
   Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-8
   PubMed Web of Science ®Google Scholar
• Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005;89:1542
   PubMed Web of Science ®Google Scholar
• Chauhan S, Kamal A, Thompson RN, Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 2009;93:984-5
   PubMed Web of Science ®Google Scholar
• Iaccheri B, Androudi S, Bocci EB, Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 2010;18:223-5
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011;50:1390-4
   PubMed Web of Science ®Google Scholar
• Freidlin J, Wong IG, Acharya N. Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br J Ophthalmol 2007;91:1414
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007;39:184-6
   PubMed Web of Science ®Google Scholar
• Rosado M, Chao H, Rose M. Severe acute thrombocytopenia following rituximab therapy. Leuk Lymphoma 2007;6:1-2
   Google Scholar
• Goldberg SL, Pecora AL, Alter RS, Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99:1486-8
   PubMed Web of Science ®Google Scholar
• Matteucci P, Magni M, Di Nicola M, Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002;100:1104-5
   PubMed Web of Science ®Google Scholar
• Whitcup SM, DeBarge LR, Caspi RR, Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol 1993;67:143-50
   PubMedGoogle Scholar
• La Heij Kuijpers RW, Baarsma SG, Adhesion molecules in iris biopsy specimens from patients with uveitis. Br J Ophthalmol 1998;82:432-7
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK, A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK, Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Gordon KB, Lebwohl MG, Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004;3:614-24
   PubMedGoogle Scholar
• Gottlieb AB, Krueger JG, Bright R, Effects of administration of a single dose of humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-35
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Krueger JG, Wittkowski K, Psoriasis as a model for T-cell-mediated disease. Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600
   PubMed Web of Science ®Google Scholar
• Uchio E, Kijima M, Tanaka S, Ohno S. Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1. Invest Ophthalmol Vis Sci 1994;35:2626-31
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006;5:197-209
   PubMed Web of Science ®Google Scholar
• Wang J, Ibrahim M, Turkcuoglu P, Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. Ocul Immunol Inflamm 2010;18:395-8
   PubMed Web of Science ®Google Scholar
• Dick AD, Meyer P, James T, Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107-9
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003;42:1539-44
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801
   PubMed Web of Science ®Google Scholar
• Jones JL, Coles AJ. Spotlight on alemtuzumab. Int MS J 2009;16:77-81
   PubMedGoogle Scholar
• Parrish C, Sobera J, Robbins C, Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 2006;5:339-40
   PubMedGoogle Scholar
• Kremer JM, Dougados M, Emery P, Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71
   PubMed Web of Science ®Google Scholar
• Kenawy N, Cleary G, Mewar D, Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2011;249:297-300
   PubMed Web of Science ®Google Scholar
• Thayu M, Markowitz JE, Mamula P, Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005;40:220-2
   PubMed Web of Science ®Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum J. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52
   PubMed Web of Science ®Google Scholar
• Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 2007;26:6-14
   PubMed Web of Science ®Google Scholar
• Sobaci G, Bayraktar Z, Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005;13:59-66
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, Efficacy of interferon alpha in the treatment of refractory and sight-threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91(3):335-9
   PubMed Web of Science ®Google Scholar